BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 19, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)
Close on Nov 18, 2026Market cap $2.15MP/E –Yield –
BioNexus Gene Lab gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
BioNexus Gene Lab's gross profit for the twelve months ending Sep 30, 2026 was $12.70K, down 99.1% year over year. For fiscal 2025 it was $1.09M, down 15.8% from the year before. The highest annual figure on record is $2.27M in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09M | -15.8% |
| FY2024 | Dec 31, 2024 | $1.29M | -3.0% |
| FY2023 | Dec 31, 2023 | $1.33M | +5.6% |
| FY2022 | Dec 31, 2022 | $1.26M | -44.5% |
| FY2021 | Dec 31, 2021 | $2.27M | +31.8% |
| FY2020 | Dec 31, 2020 | $1.72M | +2977.3% |
| FY2019 | Dec 31, 2019 | $55.89K | +94.3% |
| FY2018 | Dec 31, 2018 | $28.77K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.49K | -98.8% |
| Q2 FY2026 | Jun 30, 2026 | $12.98K | -96.5% |
| Q1 FY2026 | Mar 31, 2026 | -$790 | -100.2% |
| Q4 FY2025 | Dec 31, 2025 | -$3.98K | -101.3% |
| Q3 FY2025 | Sep 30, 2025 | $377.69K | +15.7% |
| Q2 FY2025 | Jun 30, 2025 | $368.02K | +27.5% |
| Q1 FY2025 | Mar 31, 2025 | $343.49K | -5.9% |
| Q4 FY2024 | Dec 31, 2024 | $309.23K | +16.0% |
| Q3 FY2024 | Sep 30, 2024 | $326.54K | -7.8% |
| Q2 FY2024 | Jun 30, 2024 | $288.72K | -15.0% |
| Q1 FY2024 | Mar 31, 2024 | $365.03K | -1.0% |
| Q4 FY2023 | Dec 31, 2023 | $266.56K | -21.4% |
| Q3 FY2023 | Sep 30, 2023 | $354.33K | +18.3% |
| Q2 FY2023 | Jun 30, 2023 | $339.71K | +28.7% |
| Q1 FY2023 | Mar 31, 2023 | $368.90K | +3.5% |
| Q4 FY2022 | Dec 31, 2022 | $339.23K | -28.9% |
| Q3 FY2022 | Sep 30, 2022 | $299.50K | -57.8% |
| Q2 FY2022 | Jun 30, 2022 | $263.97K | -43.5% |
| Q1 FY2022 | Mar 31, 2022 | $356.33K | -38.8% |
| Q4 FY2021 | Dec 31, 2021 | $477.17K | +24.6% |
| Q3 FY2021 | Sep 30, 2021 | $709.19K | +35.8% |
| Q2 FY2021 | Jun 30, 2021 | $467.61K | +193.6% |
| Q1 FY2021 | Mar 31, 2021 | $582.57K | -11.1% |
| Q4 FY2020 | Dec 31, 2020 | $383.00K | +1015.9% |
| Q3 FY2020 | Sep 30, 2020 | $522.22K | +6705.1% |
| Q2 FY2020 | Jun 30, 2020 | $159.29K | +3344.1% |
| Q1 FY2020 | Mar 31, 2020 | $655.31K | +6972.2% |
| Q4 FY2019 | Dec 31, 2019 | $34.32K | – |
| Q3 FY2019 | Sep 30, 2019 | $7.67K | -65.7% |
| Q2 FY2019 | Jun 30, 2019 | $4.63K | -82.0% |
| Q1 FY2019 | Mar 31, 2019 | $9.27K | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.73K | – |
| Q3 FY2018 | Sep 30, 2018 | $22.37K | – |
| Q2 FY2018 | Jun 30, 2018 | $25.65K | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.53K | – |
See a number that looks wrong?